Serotonin‐release assay‐negative heparin‐induced thrombocytopenia
- 17 October 2019
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 95 (1) , 38-47
Abstract
Heparin‐induced thrombocytopenia (HIT) is a prothrombotic drug reaction caused by platelet‐activating anti‐platelet factor 4 (PF4)/heparin antibodies. Pathogenic HIT antibodies can be detected by the serotonin‐release assay (SRA), a platelet activation test. We have regarded the SRA performed in our medical community (“McMaster” SRA) as having high sensitivity and specificity. Recently, the concept of “SRA‐negative HIT” has been proposed for enzyme‐immunoassay (EIA)‐positive/SRA‐negative patients with a HIT‐compatible clinical picture, who test positive in a PF4‐enhanced platelet activation assay. After identifying an index case of SRA‐negative HIT, we estimated the frequency of this condition by performing the “PF4‐SRA” (modified SRA using high concentrations of added PF4 rather than heparin) in EIA‐positive patients from a cohort study evaluating clinical and laboratory diagnosis of HIT. We defined SRA‐negative HIT as patients meeting three criteria: clinical picture compatible with HIT (4Ts ≥ 4 points); EIA‐positive (≥1.00 units); and PF4‐SRA‐positive. Among 430 patients, 35 were EIA‐positive/SRA‐positive and 27 were EIA‐positive/SRA‐negative. Among these 27 SRA‐negative patients, three were found to have subthreshold levels of platelet‐activating antibodies by PF4‐SRA, of whom one met clinical criteria for SRA‐negative HIT. Thus, based on identifying one patient with SRA‐negative HIT within a cohort study that found 35 SRA‐positive HIT patients, we estimate the sensitivity of the McMaster SRA for diagnosis of HIT to be 35/36 (97.2%; 95% CI, 85.8‐99.9%). Although the McMaster SRA is highly sensitive for HIT, occasional SRA‐negative but EIA‐positive patients strongly suspected of having HIT can have this diagnosis supported by a PF4‐enhanced activation assay such as the PF4‐SRA.Keywords
Funding Information
- Canadian Institutes of Health Research (201603PJT)
This publication has 35 references indexed in Scilit:
- The use of well‐characterized sera for the assessment of new diagnostic enzyme‐immunoassays for the diagnosis of heparin‐induced thrombocytopeniaJournal of Thrombosis and Haemostasis, 2010
- Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopeniaJournal of Thrombosis and Haemostasis, 2009
- Quantitative interpretation of optical density measurements using PF4‐dependent enzyme‐immunoassaysJournal of Thrombosis and Haemostasis, 2008
- What is the potential for overdiagnosis of heparin‐induced thrombocytopenia?American Journal of Hematology, 2007
- Gender imbalance and risk factor interactions in heparin-induced thrombocytopeniaBlood, 2006
- Testing for Heparin-Induced Thrombocytopenia AntibodiesTransfusion Medicine Reviews, 2006
- Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysisBlood, 2005
- Incidence and clinical relevance of heparin‐induced antibodies in patients with deep vein thrombosis treated with unfractionated or low‐molecular‐weight heparinBritish Journal of Haematology, 2002
- The epitope specificity of heparin‐induced thrombocytopeniaBritish Journal of Haematology, 1996
- Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.Journal of Clinical Investigation, 1994